You are simply missing the point. There are multiple S/T catalysts that AMBS management has laid out (within their business plan) that will unfold very shortly. If they happen to materialize in a positive way; it will give management more leverage to find more creative and suitable financing options going forward.
They could do an additional S/T bridge financing to get them through potential LymPro commercialization; however, if BD comes to bat and orchestrates a partnership and/or collaboration for LymPro (the massive dilution scenario is a foregone conclusion).
You are thinking in myopic terms; see the bigger picture.